Neutropenia is a common and dangerous toxicity of cancer therapy that profoundly affects patients' lives. Neutropenia is typically defined by the numerical value of the absolute neutrophil count. However, considering neutropenia exclusively as the numerical value of the absolute neutrophil count limits its conceptualizations to physiologically related aspects, minimizes its complexities, and neglects dimensions of human response and the patient experience. This article offers a dimensional analysis of neutropenia derived from 42 research and clinical articles. Schatzman's dimensional analysis methods were applied to the literature to identify aspects of this phenomenon lying beyond its numerical boundaries. Dimensions of neutropenia that emerged were sorted into categories of perspective, context, conditions, processes, and consequences. The presence of the same dimension in more than 1 category and the circuitous relationships among categories begin to explicate the complexity and gravity of neutropenia. Articulation of these dimensions is necessary to assemble the beginnings of a theoretical understanding of neutropenia, which is crucial for the development and application of knowledge to research and practice. Limitations evident in the literature illuminate the urgent need for research into the psychosocial as well as physiologic dimensions of neutropenia.
N eutropenia is a common and dangerous side effect of cancer therapy that is also costly in economic and human terms. It is defined in the literature as a lab value, the absolute neutrophil count (ANC). Yet within nursing practice, neutropenia represents a phenomenon that extends beyond the numerical boundaries of the ANC to include many dimensions of human experience. Although these dimensions are clearly evident in practice, they are poorly expressed and often only implied in clinical and research literature. Their articulation is necessary to assemble the beginnings of a theoretical understanding of neutropenia, which, in turn, is crucial for the development and application of knowledge to research and practice. Therefore, this article offers a dimensional analysis of neutropenia derived from scientific and clinical literature. Organizing and analyzing dimensions of neutropenia as they appear in the literature will identify aspects of this phenomenon lying beyond its numerical boundaries. Together, these dimensions reflect the complexity and gravity of a phenomenon of great significance and consequence for adults and illuminate the urgent need for research into the patient experience of neutropenia.
Ⅵ Background and Significance
Neutropenia occurs in approximately 80% of all patients undergoing treatment for cancer. 1 In 2003 cancer was estimated to afflict 1,334,100 men and women and persists as the leading cause of death in 60 to 79-year-olds, and as the second for those older than 80. 2 The exact incidence of neutropenia and the number of neutropenia-related cancer deaths are uncertain, with mortality reportedly ranging from 5% to 30% among those older than 70. 3 It is a dangerous complication. Neutropenia is without question the foremost dose-limiting toxicity of chemotherapy and renders patients vulnerable to life-threatening infection. 1 Neutropenia is associated with significant financial burden, mortality, and suffering due in large part to fever and infection. Febrile neutropenia accounts for approximately 100,000 hospitalizations a year in the United States. 1 In the most comprehensive study of its kind to date, Kuderer et al 4 studied 41,779 patients hospitalized for febrile neutropenia between 1995 and 2000. Total costs of these hospitalizations exceeded $1 billion, with a length of stay and cost for patients with hematologic malignancy twice that for patients with solid tumors (19.0 days and $28,326 for hematologic malignancy vs 8.5 days and $12,302 for solid tumors). In the same study, mortality among leukemic patients alone was 18%, twice that for all patients with solid tumors combined (9%). Further, mortality was more likely for patients older than 65 (OR ϭ 1.545, P value Ͻ .001) and for those with comorbid conditions (OR ϭ 1.625, P Ͻ .001).
Neutropenia is also associated with significant physical suffering. Patients endure fevers and chills, and symptoms specific to the site of their infection. Those with neutropenic colitis, for example, often experience severe diarrhea characterized by more than 5 episodes a day, abdominal cramping and tenderness, and fever. 5, 6 Patients who develop fungal pneumonias not only exhibit fever, dyspnea, cough, and sometimes hemoptysis, 7 but also suffer from the side effects of antifungal therapy, which can include further fevers, rigors, hypoxia, and hypotension. 8 Neutropenia even without fever and infection can be associated with suffering as patients are physically isolated, usually in private rooms, to protect them from exogenous organisms, 9, 10 and experience uncertainty as they face the possibility of life-threatening infection.
Neutropenia is typically defined according to the numerical boundaries of the ANC. However, this numerical definition of neutropenia limits conceptualizations of the phenomenon to physiologically related dimensions. This is appropriate and valuable for physiologically based studies such as those involving colony-stimulating factors (CSF) where the aim is to identify the drug's effect on the neutrophil count. The numerical boundaries of neutropenia become inadequate and lose relevance when applied to research addressing the patient experience and issues related to quality of life (QoL) that persist after the neutrophil count returns to normal levels. Count recovery may mark the end of a physiologic state, but it does not necessarily mean the experience of neutropenia has reached its conclusion. Confining conceptualizations of neutropenia to the boundaries of the ANC minimizes its complexities, and neglects dimensions of human response and the patient experience. These elements are crucial for the development of a framework for neutropenia with broad utility, one that can direct research and ultimately enable the development of specific nursing and interdisciplinary care to comprehensively meet the unique needs of the neutropenic adult with cancer.
Ⅵ Methods

Dimensional Analysis
Dimensional analysis (DA) is a particularly useful method for concept development when the aim is to illuminate a more complete picture of a complex phenomenon 11 such as neutropenia. Schatzman 12 developed this qualitative analytic technique, which involves organizing and analyzing data within an explanatory matrix in terms of perspective, context, conditions, processes, and consequences (Table 1) . By examining the definition of a phenomenon and how it is used, and organizing these dimensions into these 5 categories, the question "What all is involved here?" 12(p316) is answered in structured detail. 12, 13 Identifying and appreciating the myriad components of neutropenia as a complex clinical phenomenon then enables the development of a framework with meaning and utility for research and practice related to it.
populations (Ͼ19 years old). These searches produced approximately 1980 articles. Selected articles were those with "neutropenia" in the title, or those that were clearly about neutropenia in adult cancer patients. Excluded articles were those reporting chemotherapy trials, antibiotic trials, or those that involved neutropenic patients without cancer, or pediatric populations. Manual searches based on bibliographies of articles culled from the initial searches led to the inclusion of articles that further expanded the literature base for analysis.
Some dimensions of neutropenia evident in clinical practice did not appear in the literature elicited from database searches. Theoretical sampling, which involves intentionally selecting data that is believed will offer new information and insights, 14 provided a means by which to identify literature that might include some of these dimensions. Clinical experience and knowledge of the care of neutropenic cancer patients were used to structure manual searches of specialty journals and published abstracts to identify as many sources of information about the phenomenon of neutropenia as possible. Special emphasis was given to those clinical issues that seemed to be missing in the literature gleaned from the initial searches of computer databases. The final analysis included 42 research and clinical articles or published abstracts.
Data selection and analysis occurred simultaneously through constant comparative technique, in accordance with DA methods. 11, 13 Gradually, dimensions emerged that could be sorted into categories of perspective, context, conditions, processes, and consequences. Once a dimension within a category appeared saturated, that is, when further articles on the same topic did not reveal new information, analysis of that dimension ceased and subsequent articles addressing the same content were not added to the evolving body of literature.
Ⅵ Results
The dimensions of neutropenia revealed in this analysis were placed into categories of perspective, context, conditions, processes, and consequences (Fig 1) . "Potential and actual infection" appeared as the predominant perspective and therefore informed the organization of other dimensions. The presence of the same dimension in more than 1 category and the
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Perspective
In DA the prominent perspective is a position held by the dimension with the most "explanatory power" 13(p318) and the most fruitful starting point for explanation of the phenomenon. Of all the literature-based dimensions of neutropenia that emerged through this analysis, potential and actual infection met these criteria. Since the function of neutrophils is to form a first line of defense against infection, the state of neutropenia is synonymous with potential and actual infection. When neutrophils are deficient in number, the body is vulnerable to microorganisms from exogenous and endogenous sources. Patients are susceptible to infections arising from outside environmental sources, such as poorly cooked food, as well as from the proliferation of microorganisms normally present within the body but held in check by a fully functioning immune system. 15, 16 The literature, as this analysis will show, emphasizes the clinicians' attempts to prevent infection when patients are neutropenic, and when unsuccessful, to manage it and the related sequelae. Potential and actual infection, then, emerged as the single dimension that subsumed the others.
Context
Several of the dimensions revealed in the literature can be categorized as contextual, or those that reflect the setting or environment within which the phenomenon occurs and unfolds. For example, neutropenia is common, and caused by disease or treatment. Neutropenia can be part of the disease process in some cancers, such as leukemia, 17 but it is more often discussed as a common and severe toxicity of chemotherapy. [18] [19] [20] Neutropenia also occurs within the context of clearly delineated numerical boundaries of the ANC. A normal ANC is greater than 2.0 ϫ . 21 When authors explain their definitions of neutropenia, they commonly mention a number within this range. [22] [23] [24] [25] [26] That number exists in time and place, developing at any point during cancer patients' experience 27 as they progress through cycles of treatment and progression or resolution of their diagnoses. Neutropenia occurs across the continuum of healthcare and requires management at home, in long-term care settings, the emergency department, hospice, ambulatory outpatient units, and inpatient units. [18] [19] [20] 28, 29 Number, time, and place are among the most tangible contextual dimensions.
Accompanying these rather concrete dimensions is the more abstract context of risk, where age and other factors weigh heavily. Older adults undergoing chemotherapy are especially vulnerable to developing neutropenia. 18, 30 It is more complex and poses a greater risk than in younger cohorts partly because of the comorbid disease and organ system senescence that marks this population. 31 Once these patients are neutropenic, fever, infection, and death are ever present possibilities. 32 These possibilities are especially sharp for older adults. 31 Interestingly, none of the articles reviewed in this analysis explicitly acknowledged the risk of infection and death as something that might be concerning to patients. In each of the articles cited in this article, risk was presented as an element of neutropenia that could be used to improve management and outcomes, both physiologic and economic. Only Calhoun et al 33 implied that the risk of infection is a source of worry for patients; worry about getting an infection and worry that they might not get better are 2 items on the FACT-N subscale instrument used in their research. Distilling down the risk of death to 2 items on a questionnaire designed in theory to measure comprehensive health-related QoL, belittles patient experience and the significance and meaning of it, while failing to achieve the specificity and detail required for clinical utility.
Conditions
Risk of fever, and actual fever, as well as overt infection also surfaced through this analysis as conditions within the phenomenon, dimensions that shape the processes and consequences of neutropenia (Table 2) . Although risk of infection is an abstract contextual dimension of neutropenia, it also drives aspects of clinical care. For example, risk assessment has been incorporated into the history and physical examination of patients receiving chemotherapy, 9, 18 and can influence the treatment of neutropenia with growth factors, 18 and the setting in which patients are clinically managed. 22 278 I Cancer Nursing™, Vol. 27, No. 4, 2004 Crighton The setting in which neutropenia occurs also affects processes and consequences; low-risk patients who are managed in the ambulatory setting receive different therapeutic regimens than do those who are managed in the hospital. 34, 35 Likewise, the types of cancer patients have and the goal of their treatment affect neutropenia and its consequences. Neutropenia in patients with solid tumors receiving curative chemotherapy, for instance, has a duration less than 10 days, while in those with hematologic malignancy undergoing bone marrow transplant (BMT) it may last for as long as 20 days. 36 The risk of developing infection is related to the duration and severity of neutropenia. 16, 18, 19 Consequently, neutropenia likely will trigger a different cascade of events in each of these groups. A patient with breast cancer is neutropenic for a shorter period and therefore may develop an infection that necessitates only oral antibiotic therapy as an outpatient. 34 On the other hand, a patient with leukemia undergoing BMT may develop multiple infections that require prolonged intravenous antibiotic therapy and hospitalization. 34 Lastly, economic issues such as cost-effectiveness and costutility influence the processes and consequences of this phenomenon, albeit indirectly. For example, the use of CSF to treat febrile neutropenia is expensive, and has catalyzed efforts to develop cost-effective models of care. 37 Guidelines such as those developed by the American Society of Clinical Oncology (ASCO) incorporate the economic burden of CSF into their recommendations for their use. 38 These guidelines, in turn, shape clinical practice. Clinicians such as Budzinski and Overcash 39 used the ASCO recommendations to develop a more evidence-based approach to the administration of CSF in their management of chemotherapy-induced neutropenia. Byars 18 applied these same guidelines in an article outlining the role of the nurse in risk assessment and management for neutropenic cancer patients in the outpatient setting. Economic issues, then, influence clinical management protocols used by practitioners, and in so doing, affect the care of neutropenic patients.
The relationship between the economics of neutropenia and the patient's perspective of it as a clinical phenomenon is seemingly incongruous. Yet the articles addressing economics and the need to develop cost-effective models of care in neutropenia were the only ones reviewed during this project that acknowledged the importance of what patients think about it and its treatment. Lyman et al 40 examined the cost of febrile neutropenia and how it might influence the use of CSF. They described the importance of indirect costs such as QoL in cost-utility models and acknowledged that it is neglected in the literature. Elting and Cantor 37 also emphasized the importance of indirect costs related to QoL and addressed problems associated with measuring it. They argued that current tools to measure QoL are likely not appropriate given that episodes of febrile neutropenia are relatively brief, usually lasting 5 to 6 days. These authors also emphasized the need to hear and incorporate the patients' perspective when calculating direct and indirect costs of neutropenia. Included in these costs are out-of-pocket expenses for transportation, childcare, and housekeeping during illness. The hidden price paid for being neutropenic implies that patients require far more assistance when they are neutropenic than appears in the literature; neutropenic patients experience a loss of independence. Although Elting and Cantor 37 appreciated the impact of neutropenia on patients' lives they assumed incorrectly that QoL issues are confined to days with fever and infection. While fever during neutropenia may last only for a few days, hospitalization for febrile neutropenia and the accompanying disruption to QoL may be as long as 3 weeks.
4,36
Processes
Conditions such as type of cancer and risk influence processes unfolding within the phenomenon of neutropenia, namely, the physiologic event of the declining ANC and the clinical management of patients in this state. Neutropenia is most often referred to as a complication or toxicity of treatment. It is also frequently described with language of movement, which reflects an evolving physiologic process. Neutropenia is induced by chemotherapy and bound on the opposite end by counts that recover. 18, 33 Clinically, the counts usually fall gradually, over the course of a few days, and slowly return to normal levels over several days or weeks. 41 When the ANC falls below a designated value patients are labeled neutropenic and recovery of the counts to normal levels frees them from the restrictions and precautions to which they have been subject. 25 Numerical boundaries are valuable for physiologically based studies such as those involving CSF. In these cases, the purpose of research is to measure neutrophil production over time. 41 However, these boundaries become insufficient when the purpose of research is to describe or address aspects of neutropenia existing beyond the objective, physiologic realm. Fortner et al 42 found that significant changes in physical functioning, general health, and emotional role that were evident during neutropenia persisted after counts recovered, and were still low on the first day of the second cycle of chemotherapy. Until the conceptual boundaries of neutropenia extend beyond the value of the ANC, research addressing the patient experience and issues of QoL will persist in being relatively useless.
The physiologic process of neutropenia and its sequelae require sophisticated management, also a dimension of neutropenia that occurs over time. Many articles address the management of neutropenia as an ongoing, interdisciplinary specialty care process that warrants only the highest quality because patients are so vulnerable and the risks so great. 18, 22, 43, 44 Kirshbaum 20 recommends that ambulatory patients at risk for neutropenia have 24-hour access to an oncology registered nurse. Others argue that clinicians must follow patients who are neutropenic over time with meticulous attention to fevers, as a temperature may be the only indication of infection. 18, 45 Indeed, febrile neutropenia is an oncologic emergency that demands a process of meticulous and prompt assessment, diagnosis, and treatment. 36, [43] [44] [45] This clinical management concern results in a host of quality assurance efforts, clinical initiatives, and clinical pathways.
Quality assurance projects aimed at improving the multidisciplinary management of febrile neutropenia further illustrate management as a specialty care process. This literature also reflects the commitment of oncology specialists to educate their clinician colleagues outside the cancer community. The management of febrile neutropenia, including its prevention, detection, and treatment, requires optimal specialty knowledge 20 because the typical signs and symptoms of infection are often absent in neutropenic patients. Therefore when febrile neutropenic patients seek care in the emergency department or other care environments where clinicians are not cancer specialists fevers typically are not treated as emergent. Practitioners who are less informed regarding the implications of fevers in neutropenic patients may fail to intervene appropriately, jeopardizing patient outcomes. 27 Authors report numerous quality improvement projects aimed at febrile neutropenia. Baltic et al 43 recount an endeavor to reduce the time febrile neutropenic patients admitted to the hospital have to wait to receive antibiotics. Others describe multidisciplinary education projects to improve the general management of febrile neutropenia. 28, 29 Efforts to develop evidenced-based guidelines for the management of neutropenia itself, with CSF, also illustrate a commitment to the process of quality specialty care. 38 
Consequences
Many of these conditions and processes are also consequences of neutropenia. Fever, infection, and the risk of developing 280 I Cancer Nursing™, Vol. 27, No. 4, 2004 Crighton both were addressed above as conditions of neutropenia. Exploring their position as consequences of neutropenia illustrates the circularity of dimensions within neutropenia and the complex interactions associated with them. The consequences of neutropenia described in the literature reflect the prevailing notion that it is a physiologic phenomenon that leaves patients at risk for life-threatening infection. To prevent infection patients are instructed to exercise restrictions and take precautions that alter the course of their daily lives. In spite of these efforts, patients often do become febrile and require clinical management and intervention. They also experience symptoms while they are neutropenic that are not necessarily due to infection. The consequences of neutropenia then extend beyond the physical dimensions to include psychosocial responses and changes to their QoL (Table 3) .
PATIENTS ARE VULNERABLE TO INFECTION
Neutropenic patients are in danger of developing life-threatening infection due to the low numbers of neutrophils circulating in their blood. Whether or not patients actually develop fever and infection is clearly related to the duration and depth of neutropenia, 17, 19 and appears to depend to some degree on whether or not patients receive CSF. In a meta-analysis that Table 3 • Consequences of Neutropenia Reported in the Literature* examined the ability of CSF to decrease the depth and duration of neutropenia, investigators found that the risk of febrile neutropenia ranged from 7% to 77% in control groups compared to 0% to 63% in the CSF groups. 40 Colony-stimulating factors decreased the risk of febrile neutropenia (OR ϭ 0.38; 95% CI ϭ 0.29-0.49) and infection (OR ϭ 0.51; 95% CI ϭ 0.36-0.73). Others also have noted the impact of CSF on the incidence of febrile neutropenia. Meza et al 23 in a study in breast cancer patients receiving CSF, found that the incidence was 15% overall. However, logistic regression models showed that the predicted incidence of fever was 50% when patients were severely neutropenic for more than 5 days and did not receive CSF. The longer patients were severely neutropenic the more likely they were to develop fevers (P Ͻ .001, OR ϭ 2.28 per day). This analysis demonstrated that CSF reduced febrile neutropenia in this sample by 70%. Meza et al 23 claimed that by reducing the incidence of febrile neutropenia the incidence of infection would also fall, thereby reducing hospitalization for patients and improving QoL. The data reported by them illustrates the link between the duration of neutropenia and developing fever. However, this report did not include demographic or other descriptive information of the sample, especially regarding risk factors for febrile neutropenia, nor do Meza and colleagues offer any theoretical or empirical evidence for the connection between febrile neutropenia and QoL.
Although all neutropenic patients with cancer are inherently at risk for fever and infection, the risk is greater for some. In a large prospective study (N ϭ 756) to identify a scoring system for low-risk febrile neutropenic cancer patients several factors emerged as significant. 46 Among them were absence of hypotension, absence of chronic obstructive pulmonary disease, presence of solid tumor, and age less than 60. Although this study included patients ranging in age from 19 to 91, the average age was 52, while the median and standard deviation were not reported. Older adults with hematologic malignancies and comorbid conditions are at greater risk for the development of fever and infection according to the results of this study, but they may have been underrepresented in the sample.
Additional factors exacerbate the risk of infection due to neutropenia, such as being in the hospital 4 and the number of venous catheters patients require. 9, 24, 47 Mucositis further enhances the risk of infection by serving as a portal for organisms to enter the body. Simultaneously, it allows bacteria already present in the gastrointestinal tract to migrate, creating greater potential for infection. 16, 47 The composite of invasive procedures and microbial derangement is complex and risk laden.
Patients who are neutropenic, particularly older adults, are in significant danger of developing life-threatening infections. The administration of CSF ameliorates this risk by stimulating the body's production of neutrophils, thereby shortening the duration of neutropenia and boosting the body's ability to fight infections should they occur. Other interventions such as dietary restrictions and protective isolation are hypothesized to serve as protection for patients facing potentially lethal microorganisms.
RESTRICTIONS AND PRECAUTIONS
Clinicians teach all patients undergoing chemotherapy about restrictions and precautions they will incur when neutropenic as a side effect of their chemotherapy. Patient education revolves around the rise of neutropenia as a physiologic state in which patients are unable to fight infections. 9, 18, 29, 48 As such, teaching focuses on restrictions and precautions that are aimed at decreasing the risk of infection from exogenous sources. 36, 49 Clinicians instruct patients to monitor their temperatures carefully, sometimes twice a day, 48 and to practice meticulous hygiene. 22, 43 Dietary restrictions are a common intervention in this population but increasingly are subject to debate. Many argue the importance of a high-protein, high-calorie diet with vitamins to promote immune function and to satisfy the energy demands of tissue repair. 9, 15 However, patients often receive instructions to avoid raw eggs and vegetables, wine, beer, and tap water. 9 This is based on the hypothesis that the bacteria in food increase the risk of infection. 26 However, these same authors and others report that this is not based on evidence and is in fact a burden for patients. Even though dietary restrictions are temporary, they decrease patient choice and increase a sense of restriction or limitation. 25, 50 Rust et al 15 agree, and argue that restrictions themselves can decrease oral intake when patients' appetites are already compromised because of the side effects of chemotherapy, fever and malaise, and the side effects of antibiotics. In spite of the chemosensory changes adults face as part of the aging process and the problems of malnutrition in older adults with cancer, issues related to age, oral intake, and neutropenia appear to remain unexplored. Only Rust et al 15 acknowledged that patients have psychosocial needs regarding food and eating that clinicians should consider. All authors reviewed here failed to consider or comment on the impact such restrictions might have on QoL.
Patients who are neutropenic also tend to be physically isolated to some degree, with a rationale that the isolation will protect them from infection. Patients are given private rooms where they are unable to receive fresh flowers, drink tap water, or visit freely with family or friends who might carry viral or bacterial infections. 9, 28, 48 This physical isolation can also be socially isolating. Patients who are neutropenic are urged to avoid large crowds at home, in addition to following dietary and plant restrictions. 48 Kirshbaum 20 acknowledged that patients who are in isolation have psychosocial needs and may become depressed, especially if they are isolated for prolonged periods. While this has been documented in studies specifically addressing the experience of isolation, 51, 52 authors have neither considered these psychosocial responses as they relate to neutropenia nor the degree to which the experience may vary according to age or other demographic and contextual factors.
FEVER AND INFECTION
Efforts such as isolation and dietary restrictions are not always effective in preventing infection among patients, leaving fever and clinical infection unfortunate consequences of neutropenia. Often, the only sign of infection in this population is fever. Patients are unable to mount an inflammatory response in the absence of neutrophils. 9, 16, 18 Thus patients in the midst of an oncologic emergency do not exhibit or report the usual signs and symptoms of infection and may not look particularly sick clinically. 16, 18, 43, 45 Glauser 17 reports that over 90% of neutropenic patients with a fever have an infection. They could have a fulminant infection in any organ system but common sites include the pulmonary, gastrointestinal, and central nervous system. 44 These infections more often are caused by endogenous than by exogenous sources. 9, 20 In recent years Gram-positive organisms have dominated 16 while fungal infections and the emergence of unusual fungal strains have also become increasingly challenging. 47 If these infections go untreated, patients can die rapidly. 20 Infection-related mortality may cause 70% to 75% of all deaths in neutropenic patients with acute leukemia and 50% of all deaths in neutropenic patients with solid tumors. 9 Thus, in spite of drug therapy and other interventions intended to protect patients, fever and infection persist as significant consequences of neutropenia.
OTHER SYMPTOMS
Other consequences of neutropenia include symptoms such as bone pain, mucositis, and fatigue. Bone pain afflicts neutropenic patients who have been treated with CSF. 53 Mucositis, inflammation and destruction of mucous membranes, is usually viewed as a side effect of chemotherapy. Recently it has been linked directly to neutropenia. 54 Similarly, fatigue has been reported as a consequence of chemotherapy, 55, 56 but there is evidence to suggest it is also linked to neutropenia, albeit a link that is weak and unclear. Molassiotis and Chan 57 examined the relationship between fatigue and fever in 27 cancer patients receiving radiotherapy. They found a significant positive correlation between fatigue and body temperature and that fatigue was correlated with the ANC (r ϭ 0.51-0.55, P Ͻ .05). Schwartz 58 described patterns of fatigue in a more robust pretest posttest study with 31 women recently diagnosed with breast cancer and in an exercise program. Fatigue did not increase when patients were neutropenic. Bone pain, mucositis, and fatigue likely have direct links to neutropenia. While research is limited, it underscores the idea that patients may encounter symptoms and symptom clusters during neutropenia that are specific to the phenomenon and confined within its as yet unmarked boundaries.
PSYCHOSOCIAL RESPONSES AND ALTERATIONS IN QoL
The consequences of neutropenia, then, affect numerous aspects of patients' lives. Psychosocial responses to neutropenia and QoL are acknowledged in the literature, but remain virtually unexplored. Byars 18 refers to neutropenia being associated with "pain and suffering." 18(p36) Kirshbaum 20 refers to the psychosocial needs of patients in isolation and depression related to that isolation. Outhwaite 59 reminds clinicians that patients self-administering CSF require psychosocial support. A few investigators have begun to explore issues related to QoL in neutropenic cancer patients. Fortner and colleagues 42 have applied tools such as the SF-36 and the Psychosocial Adjustment to Illness Scale to neutropenic patients, and found that QoL declined significantly during neutropenia, in terms of physical functioning (P Ͻ .001), physical symptoms (P Ͻ .04), distress (P Ͻ .04), and social functioning (P Ͻ .04). Others are developing a QoL tool specific to neutropenia, Functional Assessment of Cancer Therapy -Neutropenia (FACT-N), which is currently undergoing validation. 33 While the development and application of QoL tools specific to neutropenia are valuable, this work is not without limitations. The SF-36, for example, measures health status, 60 not QoL, and the Fact-N was developed for use among primarily young women with breast cancer, and neglects older adults and those with hematologic malignancies. This, then, limits its utility and calls its validity into question when employed in other groups.
The consequences of neutropenia are numerous. Patients are vulnerable to microorganisms and many respond with fever and clinical infection despite restrictions and precautions imposed to protect them. These and other physical symptoms such as bone pain, mucositis, and fatigue are accompanied by psychosocial responses and alterations in QoL. All of these consequences contribute to the patient experience of neutropenia. It is equally remarkable and alarming that the patient experience of neutropenia, a common and dangerous consequence of cancer treatment, remains so neglected within nursing research. The subjective experience of neutropenia and variations according to age and development are crucial content for nurses to own to develop patient-specific care for this unique and vulnerable population.
Ⅵ Conclusions
Clearly, neutropenia is a multidimensional phenomenon. The prominent dimensions outlined here portray one of overwhelming physical significance for adults, the consequences of which extend beyond fever and infection to include interventions that intrude upon numerous aspects of daily life. These same dimensions reflect the dominance of the clinician perspective and the absence of the patient perspective. The invisible patient experience, his thoughts and emotional responses, remain undocumented and unexplored. Those patient dimensions that did emerge emphasize the physical domains of neutropenia and virtually ignore the psychosocial experience, and issues specific to older adults. This is concerning given our aging population and the epidemiology of cancer in older adults.
Neutropenia is a significant phenomenon for adults with cancer. There is an urgent need to research the patient experience and to incorporate it into the dominant dimensions of neutropenia. It is also necessary to explore and understand the connections among the many aspects of this phenomenon. Only then will it be possible to develop a framework with broad utility, one that can direct research and ultimately enable us to develop patient-specific nursing and interdisciplinary care to comprehensively meet the unique needs of the neutropenic adult with cancer.
To that end, studies of the patient experience of neutropenia might better be designed with naturalistic techniques such as qualitative description, grounded theory, or qualitative event analysis. The covert aspects of this phenomenon may be revealed only through a vantage point that deconstructs the received view of what it means to be neutropenic. Qualitative event analysis focuses inquiry on the event and emphasizes processes and interactions at work within the phenomenon. 61 In the case of neutropenia it focuses study on neutropenia as a series of events within the broader cancer experience. The dimensions of neutropenia elicited through this analysis may illuminate neutropenia as a complex web of people, relationships, and physical and psychosocial responses. Successful studies that exceed the current understanding of neutropenia must account for these processes and relationships that go beyond the conception of neutropenia as a numerical lab value that triggers fever, antibiotics, and isolation. In turn, this knowledge can serve as a foundation upon which to build nursing research and practice that better meets the needs of neutropenic adults with cancer.
